Financial Performance - The company reported a significant increase in revenue, with a year-over-year growth of 15% to $1.5 billion[7]. - The gross margin improved to 45%, up from 42% in the previous year, due to cost-saving initiatives[7]. - The company provided an optimistic outlook, projecting a revenue growth of 10-12% for the next fiscal year[7]. User Engagement - User data showed a 20% increase in active users, reaching 5 million by the end of the quarter[7]. Product Development - New product launches contributed to a 25% increase in sales in the last quarter, with the introduction of three new product lines[7]. - The company is investing $100 million in research and development for new technologies over the next two years[7]. Market Expansion - The company is expanding its market presence, planning to enter two new international markets by Q3 2024[7]. Strategic Initiatives - A strategic acquisition was completed, enhancing the company's technology capabilities and expected to generate $50 million in annual synergies[7]. - A new sustainability initiative was launched, targeting a 30% reduction in carbon emissions by 2025[7]. - The company aims to reduce operational costs by 15% through efficiency improvements in supply chain management[7]. Risks and Challenges - The company faces various risks including currency fluctuations, which could adversely impact financial condition and results of operations[19]. - The company may be affected by economic sanctions and export controls targeting Russia, which could harm business operations[19]. - The company has experienced slowing in-person customer traffic, potentially reducing sales and increasing pressure on margins[19]. - The company’s Americas Wholesale business is highly concentrated, and a decrease in purchases from any large customer could negatively impact business[21]. - The company is subject to risks related to legal and regulatory matters, which could adversely affect business and financial performance[21]. - The company’s ability to attract and retain key personnel is critical, as failure to do so could harm business operations[21]. - The company may not fully realize expected cost savings from cost-saving initiatives, which could impact profitability[19]. - The company’s reliance on its intellectual property poses risks, as methods of protection may not be adequate[19]. - The company’s stock price may be volatile, influenced by fluctuations in quarterly performance and market conditions[21]. - The company’s co-founders own a significant percentage of common stock, which may lead to differing interests from other shareholders[21].

Financial Results - Signing Day Sports, Inc. reported selected financial results for the year ended December 31, 2024, in a press release issued on April 11, 2025[5]. - The Annual Report on Form 10-K for the fiscal year ended December 31, 2024 contains an audit opinion with a going concern emphasis or qualification[8]. Company Classification - The company is classified as an emerging growth company under the Securities Act of 1933[4]. Forward-Looking Statements - The press release includes forward-looking statements that involve substantial risks and uncertainties regarding the company's future performance[7]. - The company has not undertaken any obligation to publicly update forward-looking statements except as required by law[7]. Business Updates - The press release dated April 11, 2025, is furnished as Exhibit 99.1 and contains important business updates[10]. Company Information - The company’s principal executive offices are located at 8355 East Hartford Rd., Suite 100, Scottsdale, AZ 85255[3]. - The company’s telephone number for inquiries is (480) 220-6814[3]. Regulatory Filings - The filing is intended to satisfy the obligations under the Securities Exchange Act of 1934[2]. - The company has not elected to use the extended transition period for complying with new financial accounting standards[4].

Debt and Financial Exposure - As of December 31, 2024, the company had $3.2 billion and €6.0 billion in senior interest-bearing debt, with 29.0% of this debt at variable interest rates[130] - The company has approximately $3.2 billion of U.S. dollar denominated senior debt, increasing its exposure to currency risk[132] - In 2024, €4.8 billion, or 66.6%, of the company's net revenue of €7.2 billion was denominated in U.S. dollars, exposing it to foreign currency exchange rate fluctuations[131] Operational Risks - The company relies on third parties for the sale, distribution, and delivery of its products, which could materially affect its business if these parties fail to perform[140] - The company’s manufacturing capacity could be significantly impacted by accidents or force majeure events, potentially leading to substantial revenue loss[133] - The company’s reliance on third-party suppliers for key components may impair its manufacturing ability if these suppliers fail to deliver[136] - The company’s revenue could be adversely affected by extreme weather conditions and climate change, which may increase operational risks[133] Regulatory and Compliance Challenges - The company is subject to complex and evolving data privacy regulations, which could lead to increased operational costs and compliance challenges[152] - The California Privacy Rights Act (CPRA) was enacted in November 2020, effective January 1, 2023, expanding consumer control over personal information and increasing compliance obligations for businesses[154] - Noncompliance with GDPR can result in penalties of up to €20 million or 4% of global company revenues[156] - The company faces potential costs related to compliance with various data protection regulations, which could adversely affect its business[157] - The ongoing changes and uncertainties surrounding the Affordable Care Act (ACA) could materially affect the company's operations in the United States[188] - Government pressures on reimbursement rates and pricing in the healthcare industry may adversely impact the company's financial performance[190] - The 340B Program requires the company to extend discounts, and changes to this program could negatively affect financial results[191] - The company must report detailed pricing information to CMS, and inaccuracies in this reporting could lead to fines and sanctions that adversely affect business operations[205] - Non-compliance with the 340B Program under the Public Health Service Act could lead to civil monetary penalties of up to $5,000 for each instance of overcharging covered entities[202] - Regulatory approvals are required for marketing products outside the United States, and delays in obtaining these approvals could hinder market entry and revenue generation[206] - The company is required to disclose payments to healthcare providers under the Physician Payment Sunshine Act, which imposes additional compliance costs[207] - Heightened scrutiny over pharmaceutical pricing in the U.S. could impact the company's ability to negotiate sales contracts and pricing agreements[212] - Proposed legislation targeting drug pricing may impose additional pricing pressures on the company's products, potentially affecting profitability[215] Intellectual Property and Patent Risks - The patent landscape in biotechnology is uncertain, and the company may not secure additional patents or face challenges to existing patents, impacting competitive advantage[163] - The company may be subject to substantial costs from patent litigation, which could affect its ability to compete effectively in the marketplace[175] - There is a risk of unauthorized use of the company's intellectual property, which could harm its reputation and commercial interests[169] - The company relies on trade secrets and nondisclosure agreements to protect proprietary information, but these measures may not be fully effective[170] - The company has in-licensed certain patent rights, and any failure of licensors to enforce their rights could impact the company's competitive position[177] - The company may need to obtain additional licenses or renew existing agreements, which could be uncertain and affect its ability to develop and commercialize products[178] Climate Change and Environmental Risks - Climate change poses risks to the company's operations, including physical risks like water scarcity and flooding, which could increase costs and disrupt the supply chain[182] - New regulatory requirements related to climate change may increase operating costs and necessitate additional investments in technology[183] - The company faces risks associated with environmental, health, and safety regulations, which could result in substantial liabilities and compliance costs[219] Market and Shareholder Dynamics - The Grifols Family and Scranton Enterprises B.V. own approximately 36% of Class A shares, exercising 100% voting control[226] - Class B ADSs traded as high as $11.56 on October 1, 2024, and as low as $5.47 on March 13, 2024, closing at $6.52 on April 10, 2025[227] - The company has faced negative publicity from short sellers, which may impact revenues and customer confidence[231] - Fluctuations in the exchange rate between the U.S. dollar and the euro may affect the value of ADSs and shares, increasing volatility[234] - The company may incur significant expenses defending against lawsuits resulting from negative publicity, impacting financial condition[232] - Ineffective internal controls could harm the company's ability to provide reliable financial reports, affecting market confidence[224] - The market price of shares may be influenced by various factors, including short selling and market expectations for financial performance[229] - The company intends to evaluate costs and liabilities associated with registration requirements for any rights offering[239] - The depositary may refuse to transfer ADSs under certain conditions, impacting liquidity for holders[241] Cost Management and Efficiency - A cost savings plan has been implemented to reduce headcount and improve efficiency in plasma procurement, which may lead to unexpected charges and expenses[179] - The company has acquired multiple plasma collection centers, including Canadian Plasma Resources Corporation in 2023 and Haema Plasma Kft. in 2024, as part of its plasma acquisition strategy[179]

Financial Exposure and Risks - As of December 31, 2024, the company had $3.2 billion and €6.0 billion of senior interest-bearing debt, with 29.0% of this debt bearing interest at variable rates[130] - In 2024, €4.8 billion, or 66.6%, of the company's net revenue of €7.2 billion was denominated in U.S. dollars, exposing it to foreign currency exchange rate fluctuations[131] - The company has approximately $3.2 billion of U.S. dollar denominated senior debt, increasing its exposure to currency risk[132] - Fluctuations in the exchange rate between the U.S. dollar and the euro may increase volatility and affect the value of ADSs and shares[234] Operational Risks - The company relies on third parties for the sale, distribution, and delivery of its products, which could materially affect its business if these parties fail to perform[140] - The company’s manufacturing capacity could be significantly impacted by accidents or force majeure events affecting its main facilities, which could lead to substantial revenue loss[133] - The company’s reliance on a limited number of suppliers for key components may impair its manufacturing ability if these suppliers fail to deliver on time[136] - The company may face delays in product commercialization due to the need for extensive preclinical tests and clinical trials, which are costly and time-consuming[142] - The company’s product development costs may increase significantly if it experiences delays in testing or approvals, impacting its ability to commercialize products[145] - The company’s insurance may be insufficient to cover losses from accidents or force majeure events, potentially leading to unrecoverable inventory value[135] Regulatory and Compliance Risks - The company is subject to evolving data privacy regulations, such as GDPR and CCPA, which could increase operational costs and require changes to business practices[152] - The California Privacy Rights Act (CPRA) was enacted in November 2020 and became effective on January 1, 2023, expanding consumer control over personal information and increasing compliance obligations for businesses[154] - Noncompliance with the GDPR can result in penalties of up to €20 million or 4% of global company revenues, highlighting the financial risks associated with data protection regulations[156] - The implementation of GDPR, CCPA, and other data protection requirements is expected to impose additional costs on the company, potentially affecting its business operations[157] - The company is subject to extensive government regulation and oversight, which includes compliance with the Federal Food, Drug and Cosmetic Act and the Federal False Claims Act, potentially leading to criminal and civil penalties[200] - Non-compliance with the 340B Program can result in civil monetary penalties of up to $5,000 for each instance of overcharging covered entities, adversely affecting revenues and profitability[202] - The company must report detailed pricing information to CMS, and inaccuracies could lead to fines and sanctions, impacting business operations[205] - Regulatory approvals are required for marketing products outside the U.S., and delays in obtaining these approvals could hinder commercialization efforts[206] - The company is required to report payments to healthcare providers under the Physician Payment Sunshine Act, which imposes additional compliance costs[207] - Heightened scrutiny and government efforts to increase transparency around pharmaceutical pricing could impact the company's ability to negotiate sales contracts[212] - Proposed state legislation regulating drug pricing may impose additional pricing pressures on the company's products[213] Intellectual Property Risks - The company relies on a combination of patents and trade secrets to protect its intellectual property, but there is a risk that these protections may not be sufficient against competitors[163] - Patent litigation and other intellectual property proceedings can incur substantial costs, potentially affecting the company's ability to compete effectively in the marketplace[175] - The company may face claims related to the inadvertent use of proprietary information from former employers of its employees, which could lead to costly litigation[176] - The company has in-licensed certain patent rights, and its ability to compete may depend on the performance of third-party licensors under these agreements[177] - Breaching obligations under in-license agreements could result in termination of licenses, adversely affecting the company's ability to develop and commercialize products[178] Strategic Developments - The company has acquired multiple plasma collection centers, including Canadian Plasma Resources Corporation in 2023 and Haema Plasma Kft. in 2024, as part of its plasma acquisition strategy[179] - A cost savings plan has been implemented to reduce headcount and improve efficiency in plasma procurement, which may lead to unexpected charges and expenses[179] Environmental and Health Risks - Climate change poses risks to the company's operations, including physical risks like water scarcity and flooding, which could increase costs and disrupt the supply chain[182] - New regulatory requirements related to climate change may increase operating costs and necessitate additional investments in technology[183] - The company faces risks associated with environmental, health, and safety regulations, which could lead to substantial liabilities and compliance costs[219] Market and Shareholder Risks - The Grifols Family and Scranton Enterprises B.V. own approximately 36% of Class A shares, exercising 100% voting control, which may lead to conflicts of interest with other shareholders[226] - Class B ADSs traded as high as $11.56 on October 1, 2024, and as low as $5.47 on March 13, 2024, closing at $6.52 on April 10, 2025[227] - Negative publicity from short sellers has previously created downward pressure on the market price of shares, potentially impacting revenues and customer confidence[230] - The company may face significant expenses defending against lawsuits resulting from negative publicity, which could adversely affect financial condition and results of operations[232] - Ineffective internal controls could harm the company's ability to provide reliable financial reports, affecting market confidence and trading prices[224] - The company has been subject to scrutiny and investigations by the SEC or CNMV due to negative publicity, which could divert management's attention from operations[230] - Subscription rights may be unavailable to U.S. holders of shares or ADSs, potentially leading to substantial dilution[236] - The market price of shares may be influenced by various factors, including market expectations, actual fluctuations in results, and short selling techniques[229] - The company intends to evaluate costs and potential liabilities associated with registration requirements for any future rights offerings[239] Healthcare Industry Risks - The ongoing changes and uncertainties surrounding the Affordable Care Act (ACA) could materially affect the company's operations in the United States[188] - Government pressures on pricing and reimbursement in the healthcare industry may adversely impact the company's financial performance[190] - The 340B Program requires the company to extend discounts, and changes to this program could negatively affect financial results[191] - The company anticipates increasing pricing and cost containment pressures in the healthcare industry through 2025 and beyond, which may impact reimbursement rates[192] - Off-label uses of drug products may be reimbursed by Medicare, but reductions in reimbursement could adversely affect the company's financial performance[214]

Financial Performance - Net sales for the fourth quarter were $409 million, a decrease of $46.4 million or 10.2% compared to the same period last year[6]. - For the full year, net sales decreased by $216.2 million or 13.5% to $1.386 billion, driven by declines in e-commerce and brick-and-mortar sales[14]. - Net sales for the fourth quarter ended February 1, 2025, were $408.562 million, a decrease of 10.2% compared to $455.034 million for the same period in 2024[34]. - For the fiscal year ended February 3, 2024, net sales were $1.386 billion, down from $1.602 billion in the previous fiscal year, representing a decline of 13.5%[34]. Profitability - Gross profit margin improved to 29% for the fourth quarter and 33% for the full year, reflecting a significant increase from previous periods[1]. - Adjusted net income for the full year was $5.5 million, a significant turnaround from an adjusted net loss of $(103.3) million in the prior year[20]. - The net loss for the fourth quarter was $7.990 million, significantly improved from a net loss of $128.836 million in the same quarter last year[34]. - The adjusted operating income for the fiscal year was $52.720 million, compared to an adjusted operating loss of $32.490 million in the previous year[37]. - Net loss for the fiscal year ended February 1, 2025, was $57,819 thousand, an improvement compared to a net loss of $154,541 thousand for the fiscal year ended February 3, 2024[44]. Expenses and Cost Management - Selling, general, and administrative expenses were reduced to $100.6 million in the fourth quarter, the lowest level in over 15 years[9]. - Selling, general and administrative expenses decreased to $100.574 million in the fourth quarter, down 14.5% from $117.587 million in the prior year[34]. - The company is focused on optimizing its fleet and restructuring costs to better align with market demands and consumer preferences[30]. Liquidity and Cash Flow - The company raised $90 million through a rights offering, enhancing its liquidity position[2]. - Cash and cash equivalents decreased from $13,639 thousand at the beginning of the period to $5,347 thousand at the end of the period, a decline of approximately 60.8%[44]. - The company reported net cash used in operating activities of $117,594 thousand for the fiscal year ended February 1, 2025, compared to net cash provided by operating activities of $92,800 thousand for the previous year[44]. - Net cash provided by financing activities was $128,398 thousand for the fiscal year ended February 1, 2025, compared to net cash used in financing activities of $(68,268) thousand for the previous year[44]. Store Operations - The company opened its first new store in over two years during the fourth quarter, while closing 16 stores, ending the year with 495 stores[21]. - Comparable retail sales decreased by 15.3% for the quarter, primarily due to a planned reduction in e-commerce revenue[7]. Strategic Initiatives - The company plans to enhance its omni-channel strategy and improve its product mix to drive profitable sales in fiscal 2025[4]. - The company plans to continue its strategic initiatives to enhance operational efficiencies and improve sales margins despite ongoing market challenges[30]. Balance Sheet - Total assets decreased from $800,308 thousand in February 3, 2024, to $747,552 thousand in February 1, 2025, representing a decline of approximately 6.6%[40]. - Total liabilities remained relatively stable, decreasing slightly from $809,327 thousand in February 3, 2024, to $806,963 thousand in February 1, 2025[40]. - Total current liabilities decreased from $616,404 thousand in February 3, 2024, to $518,118 thousand in February 1, 2025, a reduction of approximately 16%[40]. - The company’s stockholders' deficit increased from $(9,019) thousand in February 3, 2024, to $(59,411) thousand in February 1, 2025[40]. - The number of shares of common stock outstanding increased from 12,782 thousand to 22,013 thousand post-rights offering[43].

FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 For the fiscal year ended December 31, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________ to __________________ Commission file number 001-34499 Gulf Resources Inc. (Exact name of registrant as specified in its charter) (State or other ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to SPRING VALLEY ACQUISITION CORP. II (Exact name of registrant as specified in its charter) | Cayman Islands | 001-41529 | 98-1579063 | | --- | --- ...

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 SPRING VALLEY ACQUISITION CORP. II (Exact name of registrant as specified in its charter) | Cayman Islands | 001-41529 | 98-1579063 | | --- | --- ...

Business Overview - Forian's subscription and services-based solutions cover life sciences, pharmaceutical services, healthcare payer and provider, and financial services industries[25]. - As of February 10, 2023, Forian completed the sale of BioTrack, resulting in the cessation of software solutions for the cannabis industry, while retaining certain license rights[27]. - On October 31, 2024, Forian acquired 100% of Kyber Data Science LLC, enhancing its offerings in healthcare information products for the financial services industry[27]. - Forian's databases include billions of de-identified patient events dating back to 2014, representing the majority of the U.S. population, updated regularly to enhance data offerings[38]. - The U.S. healthcare spending is approximately 17% of GDP, with a growing emphasis on digitizing medical records and integrating disparate data sources[32]. - Forian's information products are largely subscription-based, with multi-year contracts providing tailored solutions to clients[41]. - The company aims to drive growth by acquiring new customers and increasing usage within the existing customer base through cross-selling additional information solutions[45]. - Forian's technology platform processes and integrates various data sources to produce a longitudinal database, enhancing its competitive edge in the market[44]. - The healthcare analytics market is segmented into clinical analytics, commercial analytics, and technology platform solutions, with increasing demand for integrated data solutions[33]. - Forian's competitive strengths include deep domain expertise, a diverse customer base, and a flexible approach to privacy-focused analytics software[44]. Financial Performance - Revenues for the year ended December 31, 2024, were $20,153,263, a decrease of $1,063,721 (approximately 5%) compared to $21,216,984 in 2023[150]. - Cost of revenues increased to $7,334,163 in 2024, up $1,857,131 (approximately 34%) from $5,477,032 in 2023, largely due to the Kyber acquisition and higher information licensing expenses[151]. - Gross profit as a percentage of revenues decreased to 64% in 2024 from 74% in 2023[151]. - Research and development expenses rose to $1,444,745 in 2024, an increase of $37,165 (approximately 3%) compared to $1,407,580 in 2023, influenced by the Kyber acquisition[152]. - Sales and marketing expenses decreased to $4,334,289 in 2024, down $623,544 (approximately 13%) from $4,957,833 in 2023, due to lower severance and commissions[153]. - General and administrative expenses were $12,536,940 in 2024, a slight decrease of $63,268 (approximately 0.5%) from $12,600,208 in 2023[154]. - Litigation settlements and related expenses decreased to $669,955 in 2024, down $363,030 (approximately 35%) from $1,032,985 in 2023[155]. - Adjusted EBITDA for the year ended December 31, 2024, was $489,134, a decrease of $2,509,334 compared to $2,998,468 for 2023[168]. - Net loss from continuing operations for 2024 was $(3,771,070), compared to a net income of $2,395,518 in 2023[167]. - Net cash provided by operating activities decreased to $282,827 in 2024 from $787,893 in 2023, a decline of $505,066[171]. Risks and Challenges - The company faces risks related to its limited operating history and may require additional capital for operations and expansion[59][60]. - The company depends on external data sources for its information products, which poses risks if access to this data is lost or restricted[61]. - The company’s growth strategy includes acquisitions, which may involve risks related to identifying suitable candidates and successful integration[62][63]. - The company faces risks related to the evolving federal and state privacy and data protection laws, which may increase operating costs and impact service delivery[84]. - Compliance with new privacy laws may require significant investment and could expose the company to liabilities if not adhered to properly[85]. - Cybersecurity threats pose significant risks to the company's systems and data, potentially leading to substantial costs related to rebuilding systems and defending against litigation[92]. - The competitive market for qualified personnel poses a challenge for the company in attracting and retaining necessary expertise, which could impact business continuity[77]. - Consolidation among customers may reduce service purchases, negatively affecting the company's revenue and financial condition[83]. - The company may struggle to accurately forecast operating results and growth rates, which could lead to lower-than-anticipated financial performance and stock price declines[82]. Compliance and Governance - The company has identified material weaknesses in its internal control over financial reporting, which could lead to inaccuracies in financial statements and loss of investor confidence[78]. - As of December 31, 2024, the company concluded that its disclosure controls and procedures were not effective, particularly regarding payables transactions and revenue recognition under ASC 606[79]. - The company intends to remediate identified material weaknesses, but insufficient remediation efforts could adversely affect financial reporting accuracy and compliance with SEC rules[80]. - The company has implemented practices to comply with applicable privacy laws, including engaging third parties for guidance on data de-identification[88]. - The company does not intend to pay dividends on its common stock, limiting returns to stockholders to stock price appreciation[97]. - Directors and management own approximately 46% of the company's common stock, allowing them to exert significant control over stockholder approval matters[98]. - The company is classified as an emerging growth company, allowing it to take advantage of reduced reporting requirements, which may affect its attractiveness to investors[105]. Cybersecurity and Data Management - The company prioritizes a strong cybersecurity program to safeguard sensitive information and protect its operations[110]. - The company maintains an enterprise-wide information systems security program to safeguard its information systems and assist in reporting cybersecurity incidents[115]. - The company evaluates third-party providers to manage risks associated with data breaches or cybersecurity incidents[118]. - The company has established oversight mechanisms for managing cybersecurity risks, involving regular assessments and engagement with external experts[117]. - The company relies on third-party vendors for data security, and any breaches in their systems could materially impact the company's operations and financial results[94]. Employee and Workforce - As of April 9, 2025, the company had 48 employees, with a positive relationship with its workforce and no organized work stoppages[55]. - Severance expenses for the year ended December 31, 2023, included $250,000 related to salary continuation for the former CEO[31]. - Separation expenses related to the CEO's resignation included $250,000 for salary continuation and $349,832 for accelerated vesting of stock for the six months ended June 30, 2023[218].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR (State or Other Jurisdiction of Incorporation or Organization) 60 Nexus Way, 4th Floor Camana Bay, PO Box 757, Grand Cayman, KY1-9006 (Address of Principal Executive Offices) 1 345 640 4903 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For ...